Bristol Myers Squibb is partnering with BioNTech on a closely watched cancer drug, in a deal worth billions of dollars.

AstraZeneca Plc’s experimental breast cancer pill delayed disease progression by over six months, according to data from a ...

Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

CHICAGO >> Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

Pfizer and Arvinas' experimental treatment significantly extends progression-free survival in breast cancer patients with ...

New targeted therapies allow for the treatment of a disease that is already the fifth leading cause of fatal tumors globally ...

An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to ...

A medical revolution quietly unfolds on Hainan, allowing patients to access cutting-edge therapies before they hit the market ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...